Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
973 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT00058526 | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | completed | Phase 1 | 61 | GlaxoSmithKlineINDUSTRY | 5 | May 15, 2017 |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | terminated | Phase 1 | 71 | GlaxoSmithKlineINDUSTRY | 6 | May 15, 2017 | clinicaltrials |
| NCT01248858 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. | terminated | Phase 1 | 69 | GlaxoSmithKlineINDUSTRY | 3 | May 9, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | terminated | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 4 | Mar 13, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT02109341 | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer(NabucCO) | completed | Phase 1 / Phase 2 | 148 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT02446795 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial(QUASAR) | unknown | Phase 1 / Phase 2 | 104 | Consorzio OncotechOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02573220 | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Dec 9, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00623870 | A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. | completed | Phase 1 | 116 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT00985374 | A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01513083 | A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | completed | Phase 1 | 28 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01085331 | MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 / Phase 2 | 16 | EMD SeronoINDUSTRY | 3 | Oct 19, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT00261365 | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) | completed | Phase 1 / Phase 2 | 80 | Bristol-Myers SquibbINDUSTRY | 7 | Sep 29, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01046266 | A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 62 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2016 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT02017613 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies(PI3K) | completed | Phase 1 | 35 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Jun 24, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00567879 | A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | terminated | Phase 1 / Phase 2 | 56 | Novartis PharmaceuticalsINDUSTRY | 6 | May 9, 2016 | clinicaltrials |
| NCT00876044 | A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients(QUTIE) | completed | Phase 1 | 88 | SanofiINDUSTRY | 7 | May 5, 2016 | clinicaltrials |
| NCT01955629 | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient(AMOR) | terminated | Phase 1 / Phase 2 | 4 | SanofiINDUSTRY | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01391533 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors(SARMET) | completed | Phase 1 | 72 | SanofiINDUSTRY | 4 | Apr 13, 2016 | clinicaltrials |
| NCT02723071 | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 6 | Mar 30, 2016 | clinicaltrials |
| NCT00322374 | Phase I Combination w/ Epirubicin | completed | Phase 1 | 42 | R-PharmINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00634088 | Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | terminated | Phase 1 | 13 | R-PharmINDUSTRY | 3 | Mar 10, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT02131506 | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer(CAELYX) | terminated | Phase 1 | 11 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00401609 | G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients(G-Step) | completed | Phase 1 / Phase 2 | 85 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT02616848 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | unknown | Phase 1 | 1 | Istituti Ospitalieri di CremonaOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients(NIBIT-M4) | unknown | Phase 1 | 19 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Nov 18, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials